Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis
Source : https://www.sciencedirect.com/science/article/abs/pii/S1871402122001539?via=ihub
Weekly low dose semaglutide is effective in reducing alanine aminotransferase (ALT). * This beneficial impact of injectable semaglutide is seen in people with or without type-2 diabetes. * Numbers of patients inadequate to comment on improvement in histopathologic measures of MAFLD. * Semaglutide 0.4mg/0.5 mg weekly is effective in improving ALT and other components of metabolic syndrome.
Conclusion: This meta-analysis provides reassuring data on efficacy of low dose semaglutide injections in improving ALT and certain radiologic features in MAFLD. Current conclusions are limited by small number of patients evaluated. Urgent need remains for larger studies focussing on liver biopsy.
• Source: Cardiovascular Diabetology
• Conclusions: “This meta-analysis provides reassuring data on efficacy of low dose semaglutide injections in improving ALT and certain radiologic features in MAFLD [metabolic-dysfunction associated fatty-liver disease]. Current conclusions are limited by small number of patients evaluated. Urgent need remains for larger studies focusing on liver biopsy.”
• Investigators included data from 4 RCTs representing 2115 patients. Injectable semaglutide mg once weekly decreased liver enzymes, liver stiffness, lipids, steatosis, and HbA1C. The power of the study was too low to determine the impact on MAFLD histopathology. Adverse events were comparable with controls.
• GI side effects can interfere with long-term compliance of injectable semaglutide.
• Injectable semaglutide was effective in patients with and without T2DM.